A clinical trial in patients with obesity, diabetes, and stage 4 CKD who received bardoxolone methyl demonstrated improved glycemic control, weight loss, decreased lipid accumulation, and reduced inflammation through activation of NRF2 and inhibition of NFkB [40]. Here, NFE2L2 is linked to obesity disorder.